Intervacc receives confirmation of a positive outcome for Strangvac, a vaccine against equine strangles, from the VMD in the UK

Stockholm, July 2, 2021 – Intervacc AB (“Intervacc”) announced today that the Veterinary Medicines Directorate (VMD) of the United Kingdom has give a positive outcome on their application for a Marketing Authorisation for Strangvac® within the UK. Strangvac® is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. An approval after the positive outcome is expected after 40 days.

“We are delighted to receive this positive outcome from the VMD in the UK. Our application now enters a 30-day sign-off phase followed by a 10-day issue phase, leading up to an approval for the UK market in approximately 40 days time. Up to 600 outbreaks of strangles outbreaks occur in the UK each year, impacting thousands of horses and this is an important milestone for our company as we move towards launching Strangvac®.” says Andreas Andersson, CEO of Intervacc.

“This vaccine is injected intramuscularly and has great potential to improve the health of horses as it can be used alongside current strategies as an important tool to reduce the impact of this devastating disease” commented Emma Hartman, DVM and global product manager for the vaccine. “I am really delighted that we will be launching our vaccine in the UK.”

“The positive outcome is a breakthrough for this new generation of recombinant fusion protein vaccines”, explains Dr Tim Wood, Head of CMC and Regulatory at Intervacc. “By fusing proteins together, we generate vaccines that are totally devoid of any living infectious agent, whilst simultaneously targeting multiple disease-causing mechanisms in a very selective and effective manner.”

“Strangvac® has been developed in partnership with world-leading researchers at Karolinska Institute and the Swedish University of Agricultural Sciences, SLU over many years” continues Dr Andrew Waller, Chief Scientific Officer at Intervacc. “Many of the vaccine trials were conducted at the Animal Health Trust in the UK and it is thrilling that this vaccine will soon be helping to improve the health of horses across the UK”.

For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com

This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on July 2, 2021.

About Intervacc
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company’s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10